Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer’s disease

Neurobiology of Disease

Volumn 8, Issue 4, 2001, Pages 555-567

  Poduslo, Joseph F ^a   Curran, Geoffry L ^a   Wengenack, Thomas M ^a   Malester, Brian ^b   Duff, Karen ^b  

^a MAYO CLINIC   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Albumin; Alzheimer s disease; A ; Blood brain barrier; Insulin; Protein permeability; Transgenic mice

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN; INSULIN; IODINE 125; IODINE 131; PROTEIN;

AGE; ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CATHETERIZATION; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VOLUME; BOLUS INJECTION; CONTROLLED STUDY; DIFFUSION; FEMORAL ARTERY; FEMORAL VEIN; INSULIN METABOLISM; MALE; MEMBRANE DAMAGE; MEMBRANE PERMEABILITY; MEMBRANE STRUCTURE; MOUSE; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; PROTEIN TRANSPORT; QUANTITATIVE DIAGNOSIS; RAT; STRAIN DIFFERENCE; STRUCTURE ANALYSIS; SURFACE PROPERTY; TECHNOLOGY; TRANSGENIC MOUSE;

EID: 0034870813     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.2001.0402     Document Type: Article

References (56)

1. Intravascular beta-amyloid infusion increases blood pressure: Implications for a vasoactive role of beta-amyloid in the pathogenesis of Alzheimer’s disease
2. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid
3. Blood-brain barrier integrity in Alzheimer’s disease patients and elderly control subjects
4. Characteristics of the in vitro vasoactivity of beta-amyloid peptides
5. Immunoglobulins and complement factors in senile plaques
6. Quantitative evaluation of blood-brain barrier integrity in Alzheimer type dementia: Positron emission tomographic studies with rubidium-82
7. High levels of circulating beta-amyloid peptide do not cause cerebral beta-amyloidosis in transgenic mice
8. Fate of cerebrospinal fluid-borne amyloid beta-peptide: Rapid clearance into blood and appreciable accumulation by cerebral arteries
9. Expression of β amyloid protein precursor mRNAs: Recognition of a novel alternatively spliced form and quantitation in Alzheimer’s disease using PCR
10. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer’s disease
11. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes
12. Correlative memory deficits, α-beta elevation, and amyloid plaques in transgenic mice
13. Beta-amyloid (1-42) peptide impairs blood-brain barrier function after intracarotid infusion in rats
14. Amyloid β-protein deposition in tissues other than brain in Alzheimer’s disease
15. The blood-brain barrier and cerebral microcirculation in Alzheimer disease
16. Cerebral vessels in ageing and Alzheimer’s disease
17. Overlap between pathology of Alzheimer’s disease and vascular dementia
18. Beta-amyloid vasoactivity in Alzheimer’s disease
19. Elevated Aβ42 in skeletal muscle of Alzheimer disease patients suggest peripheral alterations of AβPP metabolism
20. Secretion of Alzheimer’s disease α-beta amyloid peptide by activated human platelets
21. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer’s amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy
22. Passage of human amyloid β-protein 1-40 across the murine blood-brain barrier
23. Immunohistochemical staining of senile plaques
24. Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer’s amyloid beta in guinea pigs
25. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes
26. Isoform specific vasoconstriction induced by apolipoprotein E and modulation of this effect by Alzheimer’s β-amyloid peptide
27. Vascular basement membrane components and the lesions of Alzheimer’s disease: Light and electron microscopic analyses
28. Recent advances in the genetics of Alzheimer’s disease and vascular dementia with an emphasis on gene-environment interactions
29. Albumin and the blood-nerve barrier
30. Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy
31. Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers
32. Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers
33. Increased permeability of superoxide dismutase at the blood-nerve and blood-brain barriers with retained enzymatic activity after covalent modification with the naturally occurring polyamine, putrescine
34. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF
35. Macromolecular permeability across the blood-nerve and blood-brain barriers
36. Putrescine-modified nerve growth factor: Bioactivity, plasma pharmacokinetics, blood-brain/nerve barrier permeability, and nervous system biodistribution
37. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid β-protein 1-40 at the blood-brain barrier
38. β-sheet breaker peptide inhibitor of Alzheimer’s amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma
39. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier
40. Altered blood nerve barrier in experimental lead neuropathy assessed by changes in endoneurial albumin concentration
41. Examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga] EDTA and positron emission tomography
42. Normal and abnormal biology of the β-amyloid percursor protein
43. The origins of Alzheimer disease
44. Apolipoprotein E epsilon4 and the risk of dementia with stroke - A population-based investigation
45. Measurement of protein using bicinchoninic acid
46. Brain infarction and the clinical expression of Alzheimer disease: The nun study
47. Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage
48. Soluble Alzheimer’s beta-amyloid constricts the cerebral vasculature in vivo
49. Beta-amyloid-mediated vasoactivity and vascular endothelial damage
50. Cerebral amyloid angiopathy and Alzheimer’s disease: Two entities or one?
51. Brain parenchymal and microvascular amyloid in Alzheimer’s disease
52. Targeting of Alzheimer’s amyloid plaques
53. Quantitative histological analysis of Alzheimer’s amyloid deposition in APP, PS1 transgenic mouse brain
54. Evidence for blood-brain barrier changes in senile dementia of the Alzheimer type (SDAT)
55. Blood-brain barrier transport of circulating Alzheimer’s amyloid β
56. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer’s amyloid β